SCHEMBL9953910

SCHEMBL9953910

O=C(O)CCCCc1nc2cc(C(=O)N3CCN(c4ccccc4)CC3)ccc2nc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 6/20 0.57
▸ MAPT P10636 4/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ LMNA P02545 3/20 0.57
▸ POLB P06746 2/20 0.57
▸ MAPK1 P28482 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ CASP1 P29466 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ CASP7 P55210 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ TP53 P04637 1/20 0.52
▸ KMT2A Q03164 3/20 0.49
▸ TSHR P16473 3/20 0.48
▸ MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15378608 0.94 KMT2A (0.53) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL10210593 0.94 TP53 (0.62) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL9959515 0.94 HPGD (0.53) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL9953214 0.94 TP53 (0.59) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL15384722 0.92 HPGD (0.51) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL10210430 0.92 KMT2A (0.56) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL15378299 0.91 KMT2A (0.53) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL15383466 0.90 HPGD (0.69) HPGDMAPTALDH1A1MAPK1KDM4E
SCHEMBL15380428 0.90 KMT2A (0.66) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL15378538 0.90 TP53 (0.64) HPGDMAPTALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661428-B1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-06-07 — — EP claimed
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 — — US claimed
CN-103702985-A Quinoxalines and aza-quinoxalines as crth2 receptor modulators MERCK SHARP & DOHME 2014-04-02 — — CN claimed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 — — US claimed
EP-2661428-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2013-11-13 — — EP claimed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 — — WO claimed
EP-2661428-B1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-06-07 — — EP disclosed
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 — — US disclosed
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 — — US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 — — US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 — — US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 — — US disclosed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 HPGD 664/4885MAPT 4829/4885ALDH1A1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback